Profile data is unavailable for this security.
About the company
Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis (HT and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).
- Revenue in USD (TTM)0.00
- Net income in USD-13.62m
- Incorporated2021
- Employees7.00
- LocationConduit Pharmaceuticals Inc4851 Tamiami Trail North, Suite 200NAPLES 34103United StatesUSA
- Phone+1 (646) 491-9132
- Fax+1 (302) 655-5049
- Websitehttps://www.conduitpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dominari Holdings Inc | 12.59m | -22.69m | 10.23m | 26.00 | -- | 0.2673 | -- | 0.8126 | -3.85 | -3.85 | 2.11 | 6.10 | 0.2361 | -- | 3.80 | 484,192.30 | -42.55 | -26.82 | -44.27 | -27.45 | -- | -- | -180.22 | -3,353.52 | -- | -4.83 | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Oncotelic Therapeutics Inc | 0.00 | -4.66m | 10.31m | 22.00 | -- | 1.17 | -- | -- | -0.0115 | -0.0115 | 0.00 | 0.0217 | 0.00 | -- | -- | 0.00 | -17.29 | -25.03 | -39.98 | -48.76 | -- | -- | -- | -1,692.93 | -- | -0.5009 | 0.614 | -- | -- | -- | -255.12 | -- | -- | -- |
| ELEVAI Labs Inc | 2.45m | -5.47m | 10.46m | 18.00 | -- | 0.1166 | -- | 4.27 | -0.2924 | -0.2924 | 0.1303 | 0.1733 | 0.3826 | 0.9499 | 216.67 | 135,897.80 | -85.53 | -- | -121.34 | -- | 71.15 | -- | -223.57 | -- | 3.40 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 10.46m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -14.89m | 10.66m | 7.00 | -- | 1.77 | -- | -- | -1.72 | -1.72 | 0.00 | 0.5887 | 0.00 | -- | -- | 0.00 | -114.42 | -66.55 | -138.96 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Viaderma Inc | 17.80m | 2.31m | 10.73m | 75.00 | 0.0005 | 0.00003 | 1.98 | 0.603 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
| Turnstone Biologics Corp | 0.00 | -74.42m | 10.86m | 81.00 | -- | 0.2488 | -- | -- | -3.23 | -3.23 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -78.42 | -- | -91.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| Nascent Biotech Inc | 0.00 | -1.92m | 10.93m | -- | -- | -- | -- | -- | -0.012 | -0.012 | 0.00 | -0.003 | 0.00 | -- | -- | -- | -1,256.81 | -708.50 | -- | -- | -- | -- | -- | -589.83 | -- | -- | -- | -- | -- | -- | 25.47 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | 0.00 | -13.62m | 11.10m | 7.00 | -- | -- | -- | -- | -0.1708 | -0.1708 | 0.00 | -0.095 | 0.00 | -- | -- | 0.00 | -181.43 | -- | -- | -- | -- | -- | -- | -- | -- | -20.00 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
| Apollomics Inc | 0.00 | -57.11m | 11.14m | 45.00 | -- | 0.5338 | -- | -- | -0.568 | -0.568 | 0.00 | 0.1892 | 0.00 | -- | -- | 0.00 | -107.81 | -- | -144.29 | -- | -- | -- | -- | -- | -- | -- | 0.185 | -- | -- | -- | 28.33 | -- | -- | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 11.43m | 4.00 | -- | -- | -- | 15,238.12 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 11.89m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Lyra Therapeutics Inc | 1.47m | -97.61m | 11.91m | 87.00 | -- | 0.5775 | -- | 8.09 | -1.51 | -1.51 | 0.0229 | 0.315 | 0.0148 | -- | -- | 16,715.91 | -97.94 | -58.01 | -118.22 | -68.69 | -- | -- | -6,635.76 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Barclays Bank Plc (Private Banking)as of 30 Sep 2024 | 837.83k | 0.87% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 577.62k | 0.60% |
| Geode Capital Management LLCas of 30 Sep 2024 | 427.68k | 0.45% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 329.46k | 0.34% |
| Qube Research & Technologies Ltd.as of 30 Sep 2024 | 318.36k | 0.33% |
| Citadel Securities LLCas of 30 Sep 2024 | 189.99k | 0.20% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 184.84k | 0.19% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 183.52k | 0.19% |
| UBS Securities LLCas of 30 Sep 2024 | 168.59k | 0.18% |
| BlackRock Investment Management LLCas of 30 Sep 2024 | 125.04k | 0.13% |
